Potential Positive Effects using Coenzyme Q10 Supplement as Adjuvant Therapy to Gabapentin for Managing Diabetic Neuropathy

Authors

  • Mohammed Mahmood Mohammed Mustansiriyah university
  • Rusul AbdulKareem Hadi
  • Isam Noori Salman

DOI:

https://doi.org/10.31351/vol31iss2pp177-183

Keywords:

Diabetic neuropathy, CoQ10, Gabapentin, Neuropathy symptoms

Abstract

The most prevalent chronic complication of diabetes mellitus is diabetic neuropathy. The pathogenesis of diabetic neuropathy is exacerbated by hyperglycemia-induced oxidative stress, which causes nerves to deteriorate in a programmed manner. Many clinical trials depend on supplement in an attempt to improve neuropathy symptoms such as (pain & tingling) and patient quality of life, one of them is Coenzyme Q10 which is reported to have an anti-inflammatory and antioxidant effects, and was totally nontoxic and non-reported side effects. This study aimed to evaluate using a Coenzyme Q10 supplement as an adjuvant therapy to gabapentin to improve the clinical symptoms of diabetic neuropathy in relation to its anti-inflammatory and antioxidant effects. This open-label interventional study involved 33 diabetic neuropathy patients divided into two groups: group (1) 16 patients were given 300 mg of gabapentin once a day at evening, plus group (2) 17 patients received 300 mg of gabapentin once a day in the evening plus Coenzyme Q10 200mg once daily. Pre- and post-3 months of treatment, blood samples used to measure metabolic, anti-inflammatory and antioxidant biomarkers (fasting blood glucose, glycated hemoglobin, tumor necrosis factor-α, Iinterleukin-6 & Superoxide dismutase) , as well as the Michigan neuropathy screening instrument for  assessment of clinical symptoms. After 3 months of Coenzyme Q10 use, the results showed that the group 2 produced a highly significant change in glycated hemoglobin & fasting blood glucose levels. Meanwhile, there is no significant change in glycated hemoglobin & fasting blood glucose values in patients receiving just gabapentin. Moreover, results showed highly significant differences in Michigan neuropathy screening instrument, tumor necrosis factor-α, iinterleukin-6 & superoxide dismutase between the study groups at the completion of the research. Finally, addition of Coenzyme Q10 to gabapentin for diabetic neuropathy patients result in improving the glycemic control & symptoms of the diabetic neuropathy, as well as decreasing effects of the inflammation in addition to oxidative stress after three months of treatment.

References

Gioacchini FM, Albera R, Re M, Scarpa A, Cassandro C, Cassandro E. Hyperglycemia and diabetes mellitus are related to vestibular organs dysfunction: truth or suggestion? A literature review. Acta Diabetol.2018Dec;55(12):1201-1207.

N H Cho, J E Shaw, S Karuranga, Y Huang, J D da Rocha Fernandes, A W Ohlrogge, B Malanda. IDF Diabetes Atlas eighth edition 2017: Global estimates of diabetes prevalence for 2017 and projections for 2045 diabres.2018.02.023.

Arambewela MH, Somasundaram NP, Ranjan Jayasekara HBP, Kumbukage MP, Jayasena PMS, Hemanthi Chandrasekara CMP, et al. Prevalence of chronic complications, their risk factors, and the cardiovascular risk factors among patients with type 2 diabetes attending the diabetic clinic at a tertiary care hospital in Sri Lanka. J Diabetes Res. 2018; 1–10.

Juster-Switlyk K, Smith AG. Updates in diabetic peripheral neuropathy. F1000Res. 2016; 5: 738.

Van Deursen RW, Sanchez MM, Ulbrecht JS, et al. The role of muscle spindles in ankle movement perception in human subjects with diabetic neuropathy. Exp Brain Res. 1998; 120:1–8.

Román-Pintos LM, Villegas-Rivera G, Rodríguez-Carrizalez AD, Miranda-Díaz AG, Cardona-Muñoz EG. Diabetic polyneuropathy in type 2 diabetes mellitus: inflammation, oxidative stress, and mitochondrial function. Journal of diabetes research. 2016; 2016.

Vincent AM, Callaghan BC, Smith AL, Feldman EL (2011) Diabetic neuropathy: Cellular mechanisms as therapeutic targets. Nat Rev Neurol 7(10):573–583.

Galluzzi L, Kepp O, Trojel-Hansen C, Kroemer G. Mitochondrial control of cellular life, stress, and death. Circulation research. 2012 Oct 12; 111(9):1198-207.

Negi G, Kumar A, Joshi RP, Ruby PK, Sharma SS. Oxidative stress and diabetic neuropathy: current status of antioxidants. Institute of Integrative Omics and Applied Biotechnology Journal. 2011 Jul 1;2 (6):71-8.

Soni A, Verma M, Kaushal V, Ghalaut VS. Coenzyme Q10 therapy in current clinical practice. International Journal of Research in Medical Sciences. 2017 Jan 7; 3(4):817-25.

Motohashi N, Gallagher R, Anuradha V, Gollapudi R. Co-enzyme Q10 (Ubiquinone): It’s Implication in Improving the Life Style of the Elderly. Med Clin Rev. 2017; 3(S1):10.

Hernández-Ojeda J, Cardona-Muñoz EG, Román-Pintos LM, Troyo-Sanromán R, Ortiz-Lazareno PC, Cárdenas-Meza MA, Pascoe-González S, Miranda-Díaz AG. The effect of ubiquinone in diabetic polyneuropathy: a randomized double-blind placebo-controlled study. Journal of diabetes and its complications. 2012 Jul 1; 26(4):352-8.

Herman WH, Pop-Busui R, Braffett BH, Martin CL, Cleary PA, Albers JW, Feldman EL. DCCT/EDIC Research group use of the michigan neuropathy screening instrument as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the diabetes control and complications trial/epidemiology of diabetes interventions and complications. Diabet Med. 2012;29(7):937-44.

Downloads

Published

2022-12-24